Découvrez nos professeurs et professeures!

Frédéric Pouliot

Médecin clinicien enseignant titulaire

frederic.pouliot@fmed.ulaval.ca

Département de chirurgie

Centre de recherche sur le cancer

Centre de recherche du CHU de Québec - Université Laval

Partager la fiche :

Ce profil n’a pas encore été complété.

Projets de recherche en cours

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365..with Metastatic Castration-resistant Prostate Cancer (mCRPC)-rechARge - Bristol Myers Squibb Inc., chercheur principal - 2024-04-14 au 2030-12-25
Projet CKCis:Canadian Kidney Cancer Information System (CKCis) Site CHUQ de Québec U.Laval - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2025-03-05 au 2030-03-31
Surveillance of Complex Renal Cysts: The SOCRATIC study - Instituts de recherche en santé du Canada - Subvention Projet, Université de Sherbrooke, co-chercheur - 2019-10-01 au 2028-09-30
Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities - Instituts de recherche en santé du Canada - Subvention Projet, co-chercheur - 2022-10-01 au 2027-09-30
Analyse des vésicules extracellulaires dans le sang des hommes atteints d’un cancer de la prostate : utilité dans la stadification de la maladie et la réponse au traitement. - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2024-05-01 au 2027-05-01
Recherche pour l'optimisation de la clinique en cancer de la prostate avancé et du parcours du patient - Fondation du CHU de Québec, chercheur principal - 2025-03-17 au 2027-04-01
Multi-tracer 4-timepoint PET imaging to characterize metastatic castration-resistant prostate cancer (mCRPC) heterogeneity impact on treatment resistance in subjects beginning a new line of systemic therapy (4TMPO) - Fondation du CHU de Québec, chercheur principal - 2025-03-17 au 2027-04-01
Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice - Instituts de recherche en santé du Canada - Subvention Projet, co-chercheur - 2022-04-01 au 2027-03-31
Building a lab-on-a-chip device for the diagnosis of prostate cancer - Secrétariat des programmes interorganismes à l’intention des établissements - Fonds Nouvelles frontières en recherche - Volet Exploration, co-chercheur - 2025-03-31 au 2027-03-30
Introduction and use of PSMA radioligand therapy, Pluvicto®, for metastatic castration-resistant prostate cancer (mCRPC) patients in the Canadian Universal Health System: a real-world analysis - Fondation du CHU de Québec, chercheur principal - 2025-01-07 au 2026-03-31

...

Financements des 2 dernières années

Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial - Procure Alliance, chercheur principal - 2024-06-17 au 2025-06-16
Four-Timepoint Multi-tracer PET imaging to characterize metastatic PrOstate Cancer heterogeneity impact on treatment resistance in subjects beginning a new line of therapy - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2023-03-31 au 2025-03-31
3TMPO (Triple-Tracer strategy against Metastatic PrOstate cancer) - Fondation du CHU de Québec, chercheur principal - 2018-03-07 au 2024-03-31
Imagerie moléculaire relié au cancer de la prostate - Fondation de l'Université Laval, chercheur principal - 2023-02-01 au 2024-01-31
Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes - Ministère de la Santé et des Services sociaux, Fondation du CHU de Québec, Fondation Canadienne pour l'innovation (La) - Fonds des leaders John-R.-Evans (FLJR), co-chercheur - 2022-07-01 au 2023-12-15
Projet de recherche sur le cancer de la prostate intitulé Ironman - Fondation du CHU de Québec, chercheur principal - 2020-03-24 au 2021-03-23

...

Publications

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A, , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.4570
Reply by Authors., , The Journal of urology, 2021, 10.1097/JU.0000000000001946.03
COMPARISON OF OPEN VERSUS LAPAROSCOPIC PARTIAL NEPHRECTOMY: AVOIDING SELECTION BIAS BY MATCHED ANALYSIS, , Journal of Urology, 2009, 10.1016/s0022-5347(09)61330-6
Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5462
Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction., , Cancer prevention research (Philadelphia, Pa.), 2016, 10.1158/1940-6207.CAPR-15-0069
A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.6_suppl.32
Establishing metastatic prostate cancer quality indicators using a modified Delphi approach., , Clinical genitourinary cancer, 2022, 10.1016/j.clgc.2021.11.018
DO HIGH-VOLUME RENAL TUMOR BIOPSY CENTERS HAVE LOWER RATES OF BENIGN HISTOLOGY FOLLOWING NEPHRECTOMY FOR SMALL RENAL MASSES?, , Journal of Urology, 2018
Achieving the "trifecta" with open versus minimally invasive partial nephrectomy., , World journal of urology, 2021, 10.1007/s00345-020-03349-y
Validation of Ga-68 -Ga-DOTA-TATE using Ga-68 produced by cyclotron, , Journal of Nuclear Medicine, 2019
The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of F-Fluoromethylcholine or Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy., , Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, 10.2967/jnumed.118.225185
Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry., , BJU international, 2017, 10.1111/bju.13630
Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling., , BMC cancer, 2019, 10.1186/s12885-019-5353-6
In Vivo Detection of Prostate Cancer Cells by a PSA-Promoter Dependent Reporter Adenovirus: A Model To Image Local Recurrence after Radical Prostatectomy, , Molecular Therapy, 2009
EARLY RENAL FUNCTION OUTCOMES FOLLOWING OPEN VS LAPAROSCOPIC PARTIAL NEPHRECTOMY: HOW DO THEY COMPARE?, , Journal of Urology, 2009, 10.1016/s0022-5347(09)60997-6
First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B, , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.7_suppl.546
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR), , Journal of Clinical Oncology, 2020
Comparative analysis of scintigraphic and clinical criteria to determine success after laparoscopic pyeloplasties, , Journal of Urology, 2008, 10.1016/s0022-5347(08)60828-9
A PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF (TC)-T-99M-MIP-1404 SPECT/CT IMAGING TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH BIOPSY PROVEN LOW GRADE PROSTATE CANCER WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE (PROSPECT-AS), , Journal of Urology, 2019
Real-world utilization and safety of ipilimumab plus nivolumab (I plus N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis), , Journal of Clinical Oncology, 2020
A transcriptionally enhanced biosensor to detect and monitor biopsy-dissociated primary prostate cancer single cell drug responses by bioluminescence microscopy, , Cancer Research, 2020, 10.1158/1538-7445.Am2020-2015
Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study., , Anaesthesia, 2021, 10.1111/anae.15560
Rediscovering citrate as a biomarker for prostate cancer, Étienne Audet-Walsh, Frédéric Pouliot, Jean-Sébastien Paquette, Hermann Nabi, Ayokunle Olanrewaju, Lucas Galey, Nature Reviews Urology, 2024, 10.1038/s41585-024-00899-3
Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype., , Clinical and translational medicine, 2022, 10.1002/ctm2.581
Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience., , Cancer journal (Sudbury, Mass.), 2013, 10.1097/PPO.0b013e318292e8a4
Diagnostic performance of F-18-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of F-18-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC), , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.5012
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study., , Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 10.1158/1078-0432.CCR-20-4573
A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy., , Theranostics, 2022, 10.7150/thno.63744
Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial, , Cancer Research, 2018, 10.1158/1538-7445.Prca2017-a072
Data from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study, Barry A. Siegel, Peter R. Carroll, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Janet H. Pollard, Andrei Iagaru, Morand Piert, Kenneth L. Gage, Steve Y. Cho, Austin R. Pantel, Jeffrey Y.C. Wong, David Josephson, Frédéric Pouliot, Lawrence Saperstein, Michael A. Gorin, Steven P. Rowe, Michael J. Morris, 2023, 10.1158/1078-0432.c.6530550.v1
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients., , Clinical genitourinary cancer, 2021, 10.1016/j.clgc.2021.12.003
Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level, Frédéric Pouliot, Chantal Guillemette, Éric Lévesque, Véronique Turcotte, Louis Lacombe, Paul Toren, Fannie Morin, Patrick Caron, Bertrand Neveu, Mélanie Rouleau, Journal of Urology, 2022, 10.1097/JU.0000000000002923
Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians, , Journal of Clinical Oncology, 2020
Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.6833
A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo., , Molecular therapy : the journal of the American Society of Gene Therapy, 2013, 10.1038/mt.2012.259
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice, Fred Saad, David T. Laidley, Sebastien J. Hotte, Ricardo Rendon, Frédéric Pouliot, Tamim Niazi, Patrick Martineau, Christian K. Kollmannsberger, Urban Emmenegger, Stephan Probst, Glenn Bauman, Steven M. Yip, Kim N. Chi, Current Oncology, 2024, 10.3390/curroncol31030106
The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?, , Urologic oncology, 2021, 10.1016/j.urolonc.2021.05.026
Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC), , Journal of Clinical Oncology, 2020
Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts., , Journal of the National Cancer Institute, 1998, 10.1093/jnci/90.10.772
A prospective phase 2/3 study of PSMA-targeted F-18-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.15_suppl.e17003
Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy, Frédéric Pouliot, Dominique Guérette, Gabriel Dubois, Benoît Thériault, Michel Déry, Bertrand Neveu, Francis Lemire, Mélanie Rouleau, Jérémie Beck, The Prostate, 2023, 10.1002/pros.24501
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5187
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients, Christina Canil, Frederic Pouliot, Georg Bjarnason, Bimal Bhindi, Simon Tanguay, Antonio Finelli, Rodney H. Breau, Aly-Khan Lalani, Denis Soulières, Daniel Y.C. Heng, Nazanin Fallah-Rad, Jeffrey Graham, Naveen S. Basappa, Christian Kollmannsberger, lori wood, Camilla Tajzler, Sunita Ghosh, Ana-Alicia Beltran-Bless, Noa Shani Shrem, Cancers, 2025, 10.3390/cancers17030522
The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy, , Journal of Nuclear Medicine, 2019
Development of a multigenic bioluminescence imaging system to detect prostate cancer cells and assess their response to therapy, , Cancer Research, 2016, 10.1158/1538-7445.Am2016-4764
Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?, , BJU international, 2011, 10.1111/j.1464-410X.2010.09488.x
Validation of Ga-68-4HMSA-PSMA, a novel PSMA radioligand for PET Imaging of Prostate Cancer, , Journal of Nuclear Medicine, 2019
Figure S2 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study, Barry A. Siegel, Peter R. Carroll, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Janet H. Pollard, Andrei Iagaru, Morand Piert, Kenneth L. Gage, Steve Y. Cho, Austin R. Pantel, Jeffrey Y.C. Wong, David Josephson, Frédéric Pouliot, Lawrence Saperstein, Michael A. Gorin, Steven P. Rowe, Michael J. Morris, 2023, 10.1158/1078-0432.22480896
Modeling human bladder cancer., , World journal of urology, 2018, 10.1007/s00345-018-2369-5
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling., , Molecular cancer research : MCR, 2018, 10.1158/1541-7786.MCR-17-0784
Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration., , European urology focus, 2019, 10.1016/j.euf.2018.03.008
Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer, Fred Saad, Bobby Shayegan, Ricardo A. Rendon, Frédéric Pouliot, Tamim Niazi, Andrew Loblaw, Antonio Finelli, Christian Kollmannsberger, Canadian Urological Association Journal, 2025, 10.5489/cuaj.9100
Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System., , Clinical genitourinary cancer, 2021, 10.1016/j.clgc.2021.05.004
AUTHOR INDEX, , Asia-Pacific Journal of Clinical Oncology, 2019, 10.1111/ajco.13229
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6384
ONCOLOGICAL OUTCOMES OF PATIENTS WITH SPORADIC, NON-METASTATIC RENAL CELL CARCINOMA WITH RENAL VEIN OR INFERIOR VENA CAVA TUMOR THROMBUS, , Journal of Urology, 2019
GLUT-1, GLUT-12 AND HK2 PROTEIN EXPRESSION IN PROSTATIC ADENOCARNINOMA: CLINICAL CORRELATION WITH INTRAPROSTATIC 18F-FDG-POSITRON EMISSION TOMOGRAPHY (FDG-PET) UPTAKE, , Journal of Urology, 2013, 10.1016/j.juro.2013.02.2108
Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative., , Urologic oncology, 2021, 10.1016/j.urolonc.2021.08.016
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.6_suppl.33
Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2., , Urologic oncology, 2019, 10.1016/j.urolonc.2019.05.009
Non-clear cell histology in patients with metastatic RCC as a prognostic indicator in the targeted therapy era, , Journal of Clinical Oncology, 2012, 10.1200/jco.2012.30.5_suppl.454
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study, , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.7_suppl.543
Diagnostic Performance of PSMA-Targeted F-18-DCFPyL PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the Phase 3, Multicenter CONDOR Study, , Journal of Nuclear Medicine, 2020
Supplementary Appendix from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study, Barry A. Siegel, Peter R. Carroll, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Janet H. Pollard, Andrei Iagaru, Morand Piert, Kenneth L. Gage, Steve Y. Cho, Austin R. Pantel, Jeffrey Y.C. Wong, David Josephson, Frédéric Pouliot, Lawrence Saperstein, Michael A. Gorin, Steven P. Rowe, Michael J. Morris, 2023, 10.1158/1078-0432.22480893.v1
Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis), , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.4516
PSMA-targeted imaging with F-18-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.15_suppl.5023
A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis., , Nature communications, 2018, 10.1038/s41467-018-03278-w
Supplementary Appendix from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study, Barry A. Siegel, Peter R. Carroll, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Janet H. Pollard, Andrei Iagaru, Morand Piert, Kenneth L. Gage, Steve Y. Cho, Austin R. Pantel, Jeffrey Y.C. Wong, David Josephson, Frédéric Pouliot, Lawrence Saperstein, Michael A. Gorin, Steven P. Rowe, Michael J. Morris, 2023, 10.1158/1078-0432.22480893
Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors., , BJU international, 2018, 10.1111/bju.14041
Chylous ascites as a complication of laparoscopic donor nephrectomy., , Transplant international : official journal of the European Society for Organ Transplantation, 2005, 10.1111/j.1432-2277.2005.00219.x
Charlson Comorbidity Index as a Predictor of Cancer Mortality Beyond 10 Years after Radical Prostatectomy, , Clinics in oncology., 2019
CANCER-SPECIFIC SURVIVAL OUTCOMES OF SUNITINIB TREATMENT IN UISS RISK-STRATIFIED METASTATIC RCC PATIENTS, , Journal of Urology, 2011, 10.1016/j.juro.2011.02.2098
Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4303
CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED F-18-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL, , Journal of Urology, 2020
Reply by Authors., , The Journal of urology, 2021, 10.1097/JU.0000000000001698.02
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome., , Prostate cancer and prostatic diseases, 2020, 10.1038/s41391-020-0202-x
New developments in the imaging of metastatic prostate cancer., , Current opinion in supportive and palliative care, 2014, 10.1097/SPC.0000000000000076
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7357
Application of Canadian hereditary renal cell carcinoma risk criteria to a population database, , Journal of Clinical Oncology, 2018, 10.1200/JCO.2018.36.6_suppl.621
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6136
Proteomic identification of therapeutics targets for Enzalutamide resistance in Castration Resistant Prostate Cancer, , Cancer Research, 2017, 10.1158/1538-7445.Am2017-220
Renal cell carcinoma in the Canadian Indigenous population., , Current oncology (Toronto, Ont.), 2019, 10.3747/co.26.4707
Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens., , Scientific reports, 2016, 10.1038/srep33968
A DUAL ADENOVIRAL AMPLIFICATION SYSTEM BASED ON PSA-PROMOTER TO INCREASE SENSITIVITY OF DETECTION OF PROSTATE CANCER CELLS IN VIVO BY NON INVASIVE IMAGING, , Journal of Urology, 2010, 10.1016/j.juro.2010.02.2254
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy., , Cancer, 2010, 10.1002/cncr.24768
NON-CLEAR CELL HISTOLOGY IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOMES IN THE TARGETED THERAPY ERA, , Journal of Urology, 2012, 10.1016/j.juro.2012.02.2164
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW), , Journal of Clinical Oncology, 2020
KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC), , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.4569
Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7760
A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6667
Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy, , Journal of Clinical Oncology, 2020
Corrigendum: Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens., , Scientific reports, 2016, 10.1038/srep37381
Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy., , European urology focus, 2017, 10.1016/j.euf.2017.02.007
A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED F-18-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL, , Journal of Urology, 2020
Comparative analysis of transperitoneal and retroperitoneal laparoscopic partial nephrectomies: Laval University experience, , Journal of Endourology, 2006
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)., , The Journal of urology, 2021, 10.1097/JU.0000000000001698
Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6176
PREDICTORS OF PATHOLOGICALLY NODE POSITIVE DISEASE IN PATIENTS UNDERGOING RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR RENAL CELL CARCINOMA (RCC): RESULTS FROM THE CANADIAN KIDNEY CANCER COLLABORATION, , Journal of Urology, 2018
Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427, , Journal of Clinical Oncology, 2018, 10.1200/JCO.2018.36.15_suppl.4500
2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7074
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW), , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.6_suppl.TPS187
A prospective, multinational comparison of multi-parametric and whole body magnetic resonance imaging (mp-MRI and WB-MRI) F-18 fluoro-methyl-choline (FCH) and Ga-68 HBED-CC-(PSMA) in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy: Detection rates, management impact and treatment response, , Journal of Nuclear Medicine, 2018
Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4539
IMPACT OF TIME-TO-SURGERY AND SURGICAL DELAY ON ONCOLOGIC OUTCOMES FOR RENAL CELL CARCINOMA, , Journal of Urology, 2019
Ga-68-PSMA-617: from gallium production by cyclotron to clinical application, , Journal of Nuclear Medicine, 2020
Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner., , Molecular & cellular proteomics : MCP, 2021, 10.1016/j.mcpro.2021.100064
Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4494
CUA guideline on the management of cystic renal lesions., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4484
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426, , Journal of Clinical Oncology, 2020
RENAL BIOPSY - WHEN WILL IT CHANGE MANAGEMENT?, , Journal of Urology, 2019
Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database., , Clinical oncology (Royal College of Radiologists (Great Britain)), 2020, 10.1016/j.clon.2019.07.010
Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now, Louise Emmett, Frédéric Pouliot, European Urology, 2023, 10.1016/j.eururo.2023.07.007
Ga-68-PSMA-617: cellular evidence supporting later acquisition of PET images, , Journal of Nuclear Medicine, 2020
First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A, , Journal of Clinical Oncology, 2020
A PROSPECTIVE MULTICENTER STUDY COMPARING MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING (MP-MRI), F-18 FLUORO-METHYL-CHOLINE (FCH) AND GA-68 HBED-CC-(PSMA) POSITRON EMISSION TOMOGRAPHY IN PATIENTS BEING CONSIDERED FOR SALVAGE RADIATION THERAPY FOR BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY, , Journal of Urology, 2018
Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study., , European urology oncology., 2020, 10.1016/j.euo.2019.01.009
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.6779
Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6716
Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database, Ramy R. Saleh, Jeffrey Graham, Simon Tanguay, Aly-Khan A. Lalani, Rodney H. Breau, Nazanin Fallah-rad, Antonio Finelli, Naveen S. Basappa, Dominick Bosse, Christian K. Kollmannsberger, Frederic Pouliot, Vincent Castonguay, Daniel Yick Chin Heng, Bimal Bhindi, Georg A. Bjarnason, Lori Wood, Sunita Ghosh, Feras Ayman Moria, Changsu Lawrence Park, Current Oncology, 2024, 10.3390/curroncol31080351
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma., , The New England journal of medicine, 2019, 10.1056/NEJMoa1816714
Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients., , European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2016, 10.1093/ejcts/ezw023
Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Analysis of the PR.7 Trial., , Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 10.1158/1078-0432.CCR-18-1187
TGFβ Signaling in the Tumor Microenvironment., , Advances in experimental medicine and biology, 2021, 10.1007/978-3-030-47189-7_6
Prospective study comparing two techniques of renal clamping in laparoscopic partial nephrectomy: impact on perioperative parameters., , Journal of endourology, 2012, 10.1089/end.2011.0088
Development of a molecular imaging system based on the transcriptional activity of the DD3/PCA3 non-coding RNA for imaging specifically the prostate cancer cells, , Cancer Research, 2015, 10.1158/1538-7445.Am2015-206
Cardiac glycosides may affect prostate specific antigen levels., , The Journal of urology, 2010, 10.1016/j.juro.2010.08.052
Bisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression., , Cancers, 2021, 10.3390/cancers13215461
Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?, , Urologic oncology, 2020, 10.1016/j.urolonc.2020.06.001
A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF F-18-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCERe EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY), , Journal of Urology, 2019
Response to the Letter to the Editor, Frederic Pouliot, Nawar Touma, The Prostate, 2024, 10.1002/pros.24783
3D TISSUE ENGINEERING BLADDER MODEL FOR CANCER INVASION STUDY, , Journal of Urology, 1911
A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6862
Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation., , Drug metabolism and disposition: the biological fate of chemicals, 2020, 10.1124/dmd.119.088229
A phase Ill, multicenter study to assess the diagnostic performance and clinical impact of F-18-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR), , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.TPS5093
PROSPECTIVE STUDY COMPARING TWO TECHNIQUES OF CLAMPING IN LAPAROSCOPIC PARTIAL NEPHRECTOMY: IMPACT ON PERIOPERATIVE PARAMETERS, , Journal of Urology, 2009, 10.1016/s0022-5347(09)61340-9
Are warm ischemia and ischemia time still predictive factors of poor renal function after partial nephrectomy in the setting of elective indication?, , World journal of urology, 2015, 10.1007/s00345-014-1292-7
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial., , The Lancet. Oncology, 2020, 10.1016/S1470-2045(20)30436-8
DETERMINATION OF THE ACCURACY OF FDG-PET/CT IN THE PRIMARY STAGING OF BIOLOGICAL HIGH RISK PROSTATE CANCERS BEFORE LOCAL THERAPIES: INCREASED UPTAKE ASSOCIATED WITH HIGHLY AGGRESSIVE TUMORS, , Journal of Urology, 2013, 10.1016/j.juro.2013.02.1621
New research in kidney cancer, ASCO-GU 2017., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4607
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study., , Anaesthesia, 2021, 10.1111/anae.15458
A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer., , Oncotarget, 2016, 10.18632/oncotarget.6360
ROBOTIC VS LAPAROSCOPIC PYELOPLASTY: A TWO-CENTER INTERNATIONAL STUDY WITH LONG TERM SCINTIGRAPHIC FOLLOW-UP, , Journal of Urology, 2011, 10.1016/j.juro.2011.02.1815
Prospective, Multisite, International Comparison of F-Fluoromethylcholine PET/CT, Multiparametric MRI, and Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes., , Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, 10.2967/jnumed.118.220103
Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer., , Biochemical and biophysical research communications, 1998, 10.1006/bbrc.1998.8497
Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery., , Biomaterials, 2017, 10.1016/j.biomaterials.2017.08.041
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7355
Figure S2 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study, Barry A. Siegel, Peter R. Carroll, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Janet H. Pollard, Andrei Iagaru, Morand Piert, Kenneth L. Gage, Steve Y. Cho, Austin R. Pantel, Jeffrey Y.C. Wong, David Josephson, Frédéric Pouliot, Lawrence Saperstein, Michael A. Gorin, Steven P. Rowe, Michael J. Morris, 2023, 10.1158/1078-0432.22480896.v1
Figure S1 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study, Barry A. Siegel, Peter R. Carroll, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Janet H. Pollard, Andrei Iagaru, Morand Piert, Kenneth L. Gage, Steve Y. Cho, Austin R. Pantel, Jeffrey Y.C. Wong, David Josephson, Frédéric Pouliot, Lawrence Saperstein, Michael A. Gorin, Steven P. Rowe, Michael J. Morris, 2023, 10.1158/1078-0432.22480902.v1
Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC)., , Journal of cancer education : the official journal of the American Association for Cancer Education, 2019, 10.1007/s13187-017-1259-7
Primary and salvage cryotherapy for prostate cancer., , The Urologic clinics of North America, 2010, 10.1016/j.ucl.2009.11.007
Canadian Urological Association guideline: Management of small renal masses - Full-text., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7763
Data from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study, Barry A. Siegel, Peter R. Carroll, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Janet H. Pollard, Andrei Iagaru, Morand Piert, Kenneth L. Gage, Steve Y. Cho, Austin R. Pantel, Jeffrey Y.C. Wong, David Josephson, Frédéric Pouliot, Lawrence Saperstein, Michael A. Gorin, Steven P. Rowe, Michael J. Morris, 2023, 10.1158/1078-0432.c.6530550
Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses?, , The Journal of urology, 2018, 10.1016/j.juro.2018.04.015
Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo, Étienne Audet-Walsh, Frédéric Pouliot, Jean-Sébastien Paquette, Bertrand Neveu, Virginie Paquette, Camille Lafront, Lucas Germain, Nature Reviews Urology, 2023, 10.1038/s41585-023-00726-1
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castrationresistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW), , Journal of Clinical Oncology, 2020
A Phase 3 study of F-18-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer (CONDOR): An Analysis of Disease Detection Rate and Positive Predictive Value (PPV) by Anatomic Region, , Journal of Nuclear Medicine, 2021
Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance., , BJU international, 2011, 10.1111/j.1464-410X.2010.09871.x
18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7107
Results from the OSPREY trial A PrOspective Phase 2/3 Multi-Center Study of F-18-DCFPyL, PET/CT Imaging in Patients with PRostate Cancer - Examination of Diagnostic AccuracY, , Journal of Nuclear Medicine, 2019
Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients., , The Prostate, 2019, 10.1002/pros.23901
Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells., , International journal of molecular sciences, 2019, 10.3390/ijms20010216
Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA., , International journal of molecular sciences, 2021, 10.3390/ijms22189757
Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5154
Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models., , PloS one, 2017, 10.1371/journal.pone.0171871
A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma., , Journal of endourology, 2017, 10.1089/end.2016.0787
Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial., , The Journal of urology, 2021, 10.1097/JU.0000000000001517
Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience., , Urologic oncology, 2020, 10.1016/j.urolonc.2020.07.021
Dietary omega-3 fatty acids, genetic variation and risk of breast and prostate cancers., , World review of nutrition and dietetics, 2011, 10.1159/000327805
Immunological therapy in urological malignancy: novel combination strategies., , International journal of urology : official journal of the Japanese Urological Association, 2011, 10.1111/j.1442-2042.2010.02664.x
Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis), , Journal of Clinical Oncology, 2020
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study, , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.4500
A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT, , Journal of Clinical Oncology, 2020
CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy., , Cancer research, 2015, 10.1158/0008-5472.CAN-14-0992
An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells, Frédéric Pouliot, Bertrand Neveu, Antoine Guyon, Annie Lauzier, Cassandra Ringuette Goulet, Pallavi Jain, Imene Chebra, Audrey Champagne, Biosensors, 2024, 10.3390/bios14040175
Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy., , Current opinion in supportive and palliative care, 2018, 10.1097/SPC.0000000000000357
Contemporary management of renal tumors with venous tumor thrombus., , The Journal of urology, 2010, 10.1016/j.juro.2010.04.071
Multivariate analysis of the factors involved in loss of renal differential function after laparoscopic partial nephrectomy: a role for warm ischemia time., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011, 10.5489/cuaj.10044
PSMA Theranostics: Current Landscape and Future Outlook., , Cancers, 2021, 10.3390/cancers13164023
Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers., , European urology focus, 2021, 10.1016/j.euf.2021.10.004
CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL, , Journal of Urology, 2021
Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol., , BMJ open, 2019, 10.1136/bmjopen-2018-025662
Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens., , International journal of cancer, 1999, 10.1002/(sici)1097-0215(19990331)81:13.0.co;2-9
Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer., , The Journal of urology, 2020, 10.1097/JU.0000000000000809
DEVELOPMENT OF A MOLECULAR IMAGING SYSTEM BASED ON THE TRANSCRIPTIONAL ACTIVITY OF THE DD3/PCA3 NON-CODING RNA FOR IMAGING SPECIFICALLY THE PROSTATE CANCER CELLS, , Journal of Urology, 2015, 10.1016/j.juro.2015.02.2194
VALIDATION OF CA-IX POLYMORPHISM RS12553173 AS AN INDEPENDENT PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN METASTATIC CLEAR CELL RENAL CELL CARCINOMA, , Journal of Urology, 2010, 10.1016/j.juro.2010.02.1716
Determination of success by objective scintigraphic criteria after laparoscopic pyeloplasty., , Journal of endourology, 2010, 10.1089/end.2009.0134
EFFECT OF WARM ISCHEMIA TIME ON RENAL DIFFERENTIAL RENAL FUNCTION AFTER RENAL ARTERY CLAMPING FOR LAPAROSCOPIC PARTIAL NEPHRECTOMY, , Journal of Urology, 2009, 10.1016/s0022-5347(09)60787-4
FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy., , Cancer imaging : the official publication of the International Cancer Imaging Society, 2015, 10.1186/s40644-015-0038-0
A prospective phase 2/3 multicenter study of F-18-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY), , Journal of Clinical Oncology, 2018, 10.1200/JCO.2018.36.15_suppl.TPS5092
Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort., , Urology, 2021, 10.1016/j.urology.2021.05.053
Figure S1 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study, Barry A. Siegel, Peter R. Carroll, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Janet H. Pollard, Andrei Iagaru, Morand Piert, Kenneth L. Gage, Steve Y. Cho, Austin R. Pantel, Jeffrey Y.C. Wong, David Josephson, Frédéric Pouliot, Lawrence Saperstein, Michael A. Gorin, Steven P. Rowe, Michael J. Morris, 2023, 10.1158/1078-0432.22480902
ANTITUMOR ACTIVITY OF SUNITINIB VERSUS OTHER FDA-APPROVED TARGETED CANCER AGENTS AGAINST METASTATIC RENAL CELL CARCINOMA IN THE FIRST-LINE SETTING, , Journal of Urology, 2012, 10.1016/j.juro.2012.02.2165
EARLY POST-OPERATIVE RENAL SCINTIGRAPHY AS A PREDICTOR OF LONG TERM OUTCOMES AFTER LAPAROSCOPIC PYELOPLASTIES, , Journal of Urology, 2009, 10.1016/s0022-5347(09)61321-5
UISS RISK STRATIFICATION CAN IDENTIFY PATIENTS LESS LIKELY TO BENEFIT FROM CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA, , Journal of Urology, 2012, 10.1016/j.juro.2012.02.1079
The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol., , BJU international, 2021, 10.1111/bju.15621
OUTCOMES OF RADIOTHERAPY PLUS IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA: RESULTS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM (CKCis), , Radiotherapy and Oncology, 2020
GLUT1 expression in high-risk prostate cancer: Correlation with 18F-FDG-PET/CT and clinical outcome, , Journal of Clinical Oncology, 2020
3D tissue engineering bladder model for cancer invasion study, , Cancer Research, 2017, 10.1158/1538-7445.Am2017-5791
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.15_suppl.4500
Discordance between testosterone measurement methods in castrated prostate cancer patients., , Endocrine connections., 2019, 10.1530/EC-18-0476
HOW WELL DOES RENAL MASS SIZE MEASURED BY ULTRASOUND CORRELATE WITH MEASUREMENTS OBTAINED BY CT, MRI OR PATHOLOGY? ANALYSIS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM, , Journal of Urology, 2020
Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis., , Urologic oncology, 2019, 10.1016/j.urolonc.2019.06.006
First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B, , Journal of Clinical Oncology, 2020
Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma., , The Journal of urology, 2021, 10.1097/JU.0000000000001230
Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4397
Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7347
Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis., , Urologic oncology, 2021, 10.1016/j.urolonc.2021.02.025
Reply By Authors., , The Journal of urology, 2021, 10.1097/JU.0000000000001230.03
Ultrasound Correlates Highly with Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort., , Urology, 2022, 10.1016/j.urology.2022.02.020
Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy., , The Journal of urology, 2020, 10.1097/JU.0000000000000699
ULTRASOUND CORRELATES HIGHLY WITH CROSS SECTIONAL IMAGING FOR SMALL RENAL MASSES IN A CONTEMPORARY COHORT: RESULTS FROM THE CANADIAN KIDNEY CANCER COLLABORATION, , Journal of Urology, 2021
Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study., , CMAJ open, 2017, 10.9778/cmajo.20170005
Outcomes for patients in the pembrolizumab plus axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.6_suppl.327

...

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2020/07

Nawar Touma - Maîtrise avec mémoire - En cours
Imen Chebra - Doctorat - En cours
Mame Sokhna Sylla - Maîtrise avec mémoire - En cours
Camille Lafront - Post-doctorat - En cours
Aurélie Laurine Aloïs Grange - Doctorat - En cours
Audrey Champagne - Doctorat - 2021/05
Danahé LeBlanc - Maîtrise avec mémoire - 2021/09
Sébastien Le Batteux - Doctorat - 2022/09
Samuel Tremblay - Maîtrise avec mémoire - 2025/01

*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.

Mettre à jour mon profil de professeur(e)